CytRx receivers US patent cover for bafetinib

CytRx Corporation, a biopharmaceutical company specializing in oncology, has been granted by the US Patent and Trademark Office (US PTO) of US Patent 7,728,131 for oncology drug candidate bafetinib, encompassing claims related to bafetinib's pharmaceutical compound and composition in all indications, as well as for use in methods for treating acute and chronic myelogenous leukaemia and acute lymphoblastic leukaemia. The Issue Notification for the patent, which has a September 2025 expiration date, was received by CytRx's licensor, Nippon Shinyaku Co, LTD. CytRx holds the exclusive rights to bafetinib in all indications in the US and throughout the world, with the exception of Japan.

Comments

Post a Comment

Popular posts from this blog

GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut

Image
GOP Senator says it's hard to fund $14 billion children's health care program — then advocates for $1 trillion tax cut    Vox Author of GOP Tax Plan Says Children's Health Insurance Program Is Held Up “Because We Don't Have Money ...    The Intercept Nevada wins short reprieve in child health care funds fight    Sacramento Bee Ben McAdams: Congress to Tiny Tim: 'No health insurance for you.'    Salt Lake Tribune Full coverage
Read more

Trump wants more mental health care; Alabama says it's trying

Image
Trump wants more mental health care; Alabama says it's trying    AL.com Budget undercuts Trump focus on mental health, school safety    Yahoo News Mental health awareness license plates offered by New York State DMV    Buffalo News Trump wants to 'tackle the difficult issue of mental health?' He should put his money where his mouth is.    Washington Post Full coverage
Read more